{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:21Z","timestamp":1747181061384,"version":"3.40.5"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,23]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Polycystic kidney disease (PKD) is a genetic disorder in which the renal tubules become structurally abnormal, resulting in the development and growth of multiple cysts within the kidneys. Numerous studies on PKD have been published in the literature. However, no such articles used medical subject headings (MeSH terms) to predict the number of article citations. This study aimed to predict the number of article citations using 100 top-cited PKD articles (T100PKDs) and dissect the characteristics of influential authors and affiliated counties since 2010.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched the PubMed Central\u00ae (PMC) database and downloaded 100PKDs from 2010. Citation analysis was performed to compare the dominant countries and authors using social network analysis (SNA). MeSh terms were analyzed by referring to their citations in articles and used to predict the number of article citations using its correlation coefficients (CC) to examine the prediction effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We observed that the top 3 countries and journals in 100PKDs were the US (65%), Netherlands (7%), France (5%), J Am Soc Nephrol (21%), Clin J Am Soc Nephrol (8%), and N Engl J Med (6%); the most cited article (PMID\u2005=\u200523121377 with 473 citations) was authored by Vicente Torres from the US in 2012; and the most influential MeSH terms were drug therapy (3087.2), genetics (2997.83), and therapeutic use (2760.7). MeSH terms were evident in the prediction power of the number of article citations (CC\u2005=\u20050.37; t\u2005=\u20053.92; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.01, n\u2005=\u2005100).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A breakthrough was made by developing a method using MeSH terms to predict the number of article citations based on 100PKDs. MeSH terms are evident in predicting article citations that can be applied to future research, not limited to PKD, as we did in this study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030632","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:26:40Z","timestamp":1663943200000},"page":"e30632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Predicting the number of citations of polycystic kidney disease with 100 top-cited articles since 2010: Bibliometric analysis"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7925-0234","authenticated-orcid":false,"given":"Chen-Yu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Health Promotion and Health Education, China Medical University, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsair-Wei","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willy","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Chung San Medical University Hospital, Taichung, Taiwan"},{"name":"Department of Physical Medicine and Rehabilitation, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsien-Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Sport Management, College of Leisure and Recreation Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan"},{"name":"Department of Nephrology, Chi-Mei Medical Center, Tainan, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3904\/kjim.2021.176","article-title":"Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients.","volume":"36","author":"Oh","year":"2021","journal-title":"Korean J Intern Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease.","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease [published correction appears in N Engl J Med. 2010 Nov 11;363(20):1977] [published correction appears in N Engl J Med. 2010 Sep 16;363(12):1190].","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"100887","DOI":"10.1016\/j.disamonth.2019.100887","article-title":"Update and review of adult polycystic kidney disease.","volume":"66","author":"Colbert","year":"2020","journal-title":"Dis Mon"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/bs.mcb.2019.04.011","article-title":"Engineering kidney tissues for polycystic kidney disease modeling and drug discovery.","volume":"153","author":"Brizi","year":"2019","journal-title":"Methods Cell Biol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.03650318","article-title":"Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease.","volume":"13","author":"Messchendorp","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0040-1702223","article-title":"Publication trends and global collaborations on esophageal Atresia research: a bibliometric study.","volume":"31","author":"Feng","year":"2021","journal-title":"Eur J Pediatr Surg"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/archinte.1986.00360180247045","article-title":"Mechanism of cough with angiotensin-converting enzyme inhibition.","volume":"146","author":"Stark","year":"1986","journal-title":"Arch Intern Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/SAP.0000000000000585","article-title":"What effect does self-citation have on bibliometric measures in academic plastic surgery?","volume":"77","author":"Swanson","year":"2016","journal-title":"Ann Plast Surg"},{"key":"R12-20250504","first-page":"17","article-title":"The top 100 cited articles in lung cancer - a bibliometric analysis.","volume":"24","author":"Samanci","year":"2020","journal-title":"Contemp Oncol (Pozn)"},{"key":"R13-20250504","first-page":"1994","article-title":"Top 100 cited articles in ophthalmic epidemiology between 2006 and 2016.","volume":"11","author":"Liu","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"R14-20250504","first-page":"1","article-title":"Medical Advisory Secretariat, Health Quality Ontario. Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.","volume":"11","author":"Pron","year":"2011","journal-title":"Ont Health Technol Assess Ser"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.amjcard.2015.01.029","article-title":"Bibliometric analysis of the top 100 cited cardiovascular articles.","volume":"115","author":"Shuaib","year":"2015","journal-title":"Am J Cardiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.rmed.2018.03.014","article-title":"The 100 most influential publications in asthma from 1960 to 2017: a bibliometric analysis.","volume":"137","author":"Qu","year":"2018","journal-title":"Respir Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e11567","DOI":"10.2196\/11567","article-title":"The most-cited authors who published papers in JMIR mHealth and uHealth using the authorship-weighted scheme: bibliometric analysis.","volume":"8","author":"Kan","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1014848323806","article-title":"Journal impact measures in bibliometric research.","volume":"53","author":"Gl\u00e4nzel","year":"2002","journal-title":"Scientometrics"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejor.2015.04.002","article-title":"A review of theory and practice in scientometrics.","volume":"246","author":"Mingers","year":"2015","journal-title":"Eur J Oper Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e0212843","DOI":"10.1371\/journal.pone.0212843","article-title":"With open science gaining traction, do we need an Australasia PubMed Central (PMC)? A qualitative investigation.","volume":"14","author":"Kruesi","year":"2019","journal-title":"PLoS One"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12913-020-4974-4","article-title":"The societal economic burden of autosomal dominant polycystic kidney disease in the United States.","volume":"20","author":"Cloutier","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:20:47Z","timestamp":1746336047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":22,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030632","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}